^
Association details:
| Biomarker: | TA-MUC1 elevation + EGFR expression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | PankoMab-GEX (gatipotuzumab) (MUC1 inhibitor) + CetuGEX (tomuzotuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
Published date:
04/06/2022
Excerpt:
Patients received gatipotuzumab administered at 1400 mg every 2 weeks, 6 weeks after the start of the glyco-optimized anti-EGFR antibody tomuzotuximab at 1200 mg every 2 weeks. As this regimen was proven safe, enrollment continued in an expansion phase (EP) of patients with refractory metastatic colorectal cancer, non-small-cell lung cancer, head and neck cancer and breast cancer....In the EP, patients with baseline sTA-MUC1 levels above the median appeared to have improved progression-free survival and overall survival.4/6/2022
DOI:
10.1016/j.esmoop.2022.100447
Trial ID:
